Elevar, Hengrui eye quick refile for PD-1 liver cancer combo after surprise FDA rejection

After a meeting with the FDA last week, Elevar Therapeutics and Jiangsu Hengrui Pharma are preparing to refile their PD-1 combination potentially as early as October, Elevar’s CEO Saeho Chong, Ph.D., said.